We value your privacy
We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
No cookies to display.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
No cookies to display.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
No cookies to display.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
No cookies to display.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
No cookies to display.
Primary Care Patients’ and Staff’s Perceptions of Self-Rooming as Alternative to Waiting Rooms
Most patients (n = 1,561) preferred self-rooming (86%), especially among patients aged <65 years and in family medicine clinics. Self-rooming is a patient-centered innovation that is also acceptable to staff. We demonstrated that pragmatic implementation is feasible across primary care without expensive technology or specially designed buildings.
Full Access: Annals of Family Medicine
Vibrating Pill for Constipation Now Available
In a trial, the pill produced at least one additional weekly bowel movement for 41% of participants, compared to at least one additional bowel movement for 23% of participants who took a placebo pill. Vibrant was approved by the FDA in August but is just now becoming available for doctors to prescribe. Because it is not a drug, Vibrant is considered a Class 2 medical device by the FDA, which is the same class as contact lenses.
Full Access: Medscape
Early Treatment with Pegylated Interferon Lambda for Covid-19
A randomized, controlled, adaptive platform trial in Brazil and Canada showed that a total of 25 of 931 patients (2.7%) in the interferon group had a primary-outcome event, as compared with 57 of 1018 (5.6%) in the placebo group, a difference of 51%. Among predominantly vaccinated outpatients with Covid-19, the incidence of hospitalization or an emergency department visit (observation for >6 hours) was significantly lower among those who received a single dose of pegylated interferon lambda than among those who received placebo.
Full Access: NEJM
Norovirus National Trends
The percentage of positive norovirus tests at the end of January has surpassed the peak percentage seen last year in March, according to surveillance data collected by the Centers for Disease Control and Prevention. Though the data suggests the virus may have peaked on a national level, regional data shows cases are still floating upward in the Northeast, Midwest, and Western US, with numbers in the South seemingly sinking. The latest wave of infectious diseases in the US comes as the country is still grappling with COVID-19 spread while other germs are reestablishing their normal cycles.
Full Access: CDC
Notifications